Skip to content
News
Firebrick Raises $800,000 via Placement

Firebrick Raises $800,000 via Placement


Firebrick Pharma Limited (ASX: FRE) is pleased to announce that it has received binding commitments for a placement of $800,000, comprising 16 million shares at $0.05 per share (Placement). GZ Family Holdings Pty Ltd, an existing substantial holder in Firebrick, has committed to take up 14 million shares ($700,000 of the Placement) and 2 million…

Nasal disinfection as a front-line defence in future pandemics

Nasal disinfection as a front-line defence in future pandemics


Recently, Professor Peter Friedland presented at the Australian Military Medical Association conference (12 – 15 October 2023), with the title of his presentation being: “Nasal Disinfection as a Front-line Defence in Future Pandemics”. Read the published abstract here To view the full presentation, please click here Disclosure: the presentation is the view of the presenter…

Firebrick Phase 3 Trial fully recruited with 500 subjects

Firebrick Phase 3 Trial fully recruited with 500 subjects


Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine® Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of the complete efficacy data and timely completion of the statistical analysis, we expect to report headline results of the trial by…

Investor Update on Key Projects

Investor Update on Key Projects


We are pleased to provide the following update on the Company’s key projects, which will be provided verbally by the Executive Chairman at a General Meeting of Shareholders, today. Phase 3 clinical trial of Nasodine® Nasal Spray (Nasodine): This trial started in 2022 and is a pivotal trial of Nasodine as a treatment for the…

Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment

Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment


Firebrick Pharma is pleased to provide an update on the progress of the confirmatory Phase 3 clinical trial of Nasodine® Nasal Spray as a treatment for the common cold. The study, which commenced in 2022, aims to recruit 196 subjects with early-stage colds who are confirmed by PCR to have a viral infection (other than…

Nasodine research points to potential role in CRS

Nasodine research points to potential role in CRS


We are pleased to announce the publication of new research into Nasodine ® Nasal Spray (“Nasodine”) identifying its potential in the management of chronic rhinosinusitis (CRS). Sponsored by Firebrick, the research was conducted at the University of Auckland and has now been published in the prestigious journal, The Laryngoscope1. “To date, the development of Nasodine…